Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Berodual® Respimat® 20/50µg/Dose Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men and women presenting with the symptoms of chronic obstructive airways disease were given Berodual® Respimat® 20/50µg/dose solution for inhalation only where this was considered necessary in medical terms
- Patients who have not been treated prior to the post-marketing surveillance study as well as patients who have been treated with Berodual® metered dose inhaler (MDI) or other respiratory medications prior to the Post-Marketing Surveillance Study could be included
Exclusion Criteria:
- Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
chronic obstructive airways disease patients
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with adverse drug reactions
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
Change in overall severity of clinical picture rated on 3-point scale
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
Change in breathlessness rated on a 4-point scale
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
Change in restriction of activity due to breathlessness rated on a 4-point scale
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
Change in number of awakening due to nocturnal breathlessness rated on 4-point scale
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
Global assessment of efficacy by the patients rated on 5-point scale
Time Frame: after 4, 8 and 12 weeks
|
after 4, 8 and 12 weeks
|
|
Global assessment of efficacy by the investigator rated on 5-point scale
Time Frame: after 4, 8 and 12 weeks
|
after 4, 8 and 12 weeks
|
|
Assessment of tolerability on a 5-point scale
Time Frame: after 4, 8 and 12 weeks
|
after 4, 8 and 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 215.1363
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.